Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
0.994
+0.034 (3.51%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.

Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.

The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.

It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.

Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia.

The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Rallybio Corporation
Rallybio logo
Country United States
Founded 2018
IPO Date Jul 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 43
CEO Stephen Uden

Contact Details

Address:
234 Church Street, Suite 1020
New Haven, Connecticut 06510
United States
Phone 203 859 3820
Website rallybio.com

Stock Details

Ticker Symbol RLYB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $13.00
CIK Code 0001739410
CUSIP Number 75120L100
ISIN Number US75120L1008
Employer ID 85-1083789
SIC Code 2834

Key Executives

Name Position
Dr. Stephen Uden M.B, M.D. Co-Founder, President, Chief Executive Officer and Director
Dr. Martin W. MacKay Ph.D. Co-Founder and Executive Chairman
Jonathan I. Lieber M.B.A. Chief Financial Officer and Treasurer
Dr. Steven W. Ryder F.A.C.P, M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Sep 17, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jul 30, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jul 30, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jul 23, 2024 8-K Current Report
May 21, 2024 8-K Current Report